Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

目录号：S1098 别名： PF-01367338 中文名称：瑞卡帕布磷酸盐

Rucaparib (AG-014699) phosphate Chemical Structure

CAS No. 459868-92-9

Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂，无细胞试验中作用于PARP1的Ki为1.4 nM，对其余8个PARP位点也有结合亲和力。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1091.92 现货
RMB 980.68 现货
RMB 1730.04 现货
RMB 5483.69 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Rucaparib (AG-014699) phosphate发表文献103篇：

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂，无细胞试验中作用于PARP1的Ki为1.4 nM，对其余8个PARP位点也有结合亲和力。Phase 3。
特性 AG-014699是第一个用于人类癌症疗法的PARP 抑制剂。
靶点
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外研究

AG-014699有效抑制纯化的全长人类PARP-1，作用于LoVo和SW620细胞显示出强PARP抑制效果。AG-014699是AG14447的磷酸盐形式，且是第一个和temozolomide联用用于临床实验的PARP抑制剂。[1] AG-014699的辐射增敏性是由于下游NF-κB激活的抑制，及SSB修复抑制。AG-014699可以作用于DNA损伤激活的NF-κB，且克服传统NF-κB抑制剂的毒性，不会损害其他重要的炎症反应。[2]1μM AG-014699作用于D283Med细胞时抑制PARP-1活性达97.1%。[3]在NB-1691, SH-SY-5Y, 和SKNBE(2c)细胞中AG-014699明显增强Topotecan和Temozolomide的细胞毒性。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M4q1TmZ2dmO2aX;uJGF{e2G7 M3\LclAvOS9zL{WwNE8yODByIH7N MoPsbY5pcWKrdIOgVGFTWCCjY4Tpeol1gSCjdDDzeIFzfGmwZzDjc45k\XKwdILheIlwdiCxZjC1NFAhdk1? MoLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
BT474 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\rS|UxOCCwTR?= NVjhXpF3OTEkgKOxOeKh\A>? MoS5doVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{OES1OUc,OjVzMki0OVU9N2F-
SKBR3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ENVUxOCCwTR?= NYXCZ2J4OTEkgKOxOeKh\A>? NUSzS|FKemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? NIf0NFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
AU565 M1XqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCxeXlQPTByIH7N M1POOFEx6oDVMUZCpIQ> M2\kVJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{OES1OUc,OjVzMki0OVU9N2F-
EFM192A MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjGRYdpPTByIH7N NHn5c2syOOLCk{G1xsBl M2nQPJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> M3rUS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
MDA-MB-231 M2P6NmZ2dmO2aX;uJGF{e2G7 NELrWY4yOC9{MD:0NEDPxE1? NHK2e5gzPCCq NVzPZYFCcW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF:yTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231 NHn5[2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVmwMlEuPDBizszN NEWxToEzPCCq Ml\VTWM2OOLCiU5ihKkyPy55N9Mg{txO MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 M3vFZ2Fxd3C2b4Ppd{BCe3OjeR?= NHrrfGoyOC9{MD:0NEDPxE1? MkPjNlQhcA>? NG[5XYRqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M4T0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKwNVUzLz5{NESyNFE2OjxxYU6=
MDA-MB-231 M3fMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMUYVWOTBxMkCvOFAh|ryP MnG2NlQhcA>? NFrzT4djdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCrbjDHNk9OKHCqYYPl NIPFfmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
H460 NWDqWlByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnDOFAxKG6P MoPaNlTDqGh? M1rTOolv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 Mn;4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUG2NVEoRjJ2NEGxOlEyRC:jPh?=
A549  M3e0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WwTlQxOCCwTR?= NVfoUIdDOjUEoHi= MnfVbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUG2NVEoRjJ2NEGxOlEyRC:jPh?=
DT40 NEj2enRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXWcWJMUUN3ME2yNUBvVQ>? NX3keoQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVY5OTNpPkK0N|U3QDF|PD;hQi=>
DU145 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PjXGlEPTB;MUigcm0> MkTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
COLO704 M4HCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;3coR7UUN3ME2yMlUzKMLzIECuOlch|ryP NHTmfFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVMANAb NUHkfo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXITWM2OD1{LkW4JOKyKDBwM{ig{txO NX;ybFBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV177 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:zVWlEPTB;Mj63PEDDuSByLkexJO69VQ>? NFzPW4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OAW28 M{DyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\STWM2OD1|Lk[xJOKyKDBwMkig{txO NHLCdlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVSAHO MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\GcJRKSzVyPUOuOlQhyrFiMD6zN{DPxE1? NHXPTpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVKATE NVXjOpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwNkSgxtEhOS55OTFOwG0> NIOweHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCAR3 NXXhPYs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMfGlEPTB;Mz63OEDDuSByLkSwJO69VQ>? MnzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
PEO14 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLFTWM2OD1|Lki0JOKyKDBwN{[g{txO M1v0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
A2780 M4joPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe4WodKSzVyPUOuPVQhyrFiMD6yOUDPxE1? M3n2Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVTOKO NUDI[pczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwMUSgxtEhOS53MzFOwG0> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KURAMOCHIb NVTN[GtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD12LkO0JOKyKDBwMkmg{txO NWnldlNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
TOV21G NXfte5luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwMEegxtEhOS5|MDFOwG0> M1zCT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVISE MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ewZmlEPTB;NT62PEDDuSByLkKzJO69VQ>? M{j5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZwMUWgxtEhOS52MjFOwG0> NUTaSopvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
RMUGS NV7IZ|hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXRTWM2OD15LkCzJOKyKDFwOEOg{txO M4D3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
PEO6 M4S0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7UV5BDUUN3ME23MlA3KMLzIECuO|Qh|ryP NIr5clI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA429 NGLMVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwMkmgxtEhOS54NDFOwG0> NUD0N4k3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV167 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHSTWM2OD16LkOzJOKyKDFwMUig{txO M2fIcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
RMG1 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDsWndKSzVyPUmuN|IhyrFiMj6zOkDPxE1? M4DBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR5 NEXSSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDtTWM2OD17LkWwJOKyKDJwNUmg{txO Mo\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
EFO21 NXnqfpV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXYNphKSzVyPUmuPVIhyrFiMT64O{DPxE1? NFTtfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
ES2 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzaTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? NXS0WZlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
Tyk-nu M1PEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPoN5BiUUN3ME2xNE4zOCEEsTCxMlEzKM7:TR?= MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
CAOV3 NHv3RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\nTIVKSzVyPUGwMlM4KMLzIECuPFch|ryP MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OV207 NYj3[ld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPETWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? M4jPRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
HEY M3HZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\FT3ZCUUN3ME2xN{4xOSEEsTCwMlc2KM7:TR?= NHjkW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
DOV13 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[ycmlEPTB-MUWg{txO MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO27 M2LuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rWN2lEPTB-MUWg{txO MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
HEY C2 M1TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRjF3IN88US=> NIPlVVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KOC-7cc NF7YNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fidGlEPTB-MUWg{txO MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
MCASb MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRjF3IN88US=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OAW42 NH7r[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[yTWM2OD5zNTFOwG0> NWfwO4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV2008 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjRUllmUUN3ME6xOUDPxE1? M1;yZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV90 NGPTO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;NTWM2OD5zNTFOwG0> M3HmcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCA420b MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXjbVNKSzVyPkG1JO69VQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCA432 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UU5RKSzVyPkG1JO69VQ>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
PEA2 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPYTWM2OD5zNTFOwG0> NIPjWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
SKOV3 NGDiTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRjF3IN88US=> NY\XSWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
TOV112D NFexdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfxOZgxNTNizszN NXPEVJJ4UUN3ME6xOUDPxE1? NWrQVZgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
C4-2 NGPBWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVMh|ryP M4\HblE1KGR? MoTZSG1UVw>? NHjWfnRl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 Mn[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
PC3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvDcm8yOC1|IN88US=> NWDzTYJ6OTRiZB?= NGPOOnhFVVOR NWjac|lF\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
DU145 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET3dGgxNTNizszN MWqxOEBl M3PmS2ROW09? NInYXZFl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
VCaP  NFfySXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;le3gxNTNizszN MXixOEBl M2rSPGROW09? MXPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
LNCaP  MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZSVIxNTNizszN MWWxOEBl M2PpeGROW09? NHvCdoFl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
MDA-MB-468 NFvOVo1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1PIdmlEPTB;OT63JO69VQ>? M{nRSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nke4NVYyLz5{Mk[3PFE3OTxxYU6=
MDA-MB-231 NVvPUGdGS2WubDDWbYFjcWyrdImgRZN{[Xl? MmnyTWM2OD1zMzFOwG0> NETmWGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
Cal-51 M4\ZcGNmdGxiVnnhZoltcXS7IFHzd4F6 M{XTfmlEPTB;OD62JO69VQ>? NWHOV3VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O|gyPjFpPkKyOlc5OTZzPD;hQi=>
LoVo M3LYOmZ2dmO2aX;uJIF{e2G7 MoXPN|AhdWmwcx?= M1zLT2lvcGmkaYTpc44hd2ZiUFHSVEBqdiCqdX3hckBNd1[xIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YheG:ueTjBSHAqNXKrYn;z[UBxd2y7bXXybZpifGmxbjDmc5IhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkCwOFY6KM7:TT6= NHL1dlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MX1 NGrRU4tEgXSxdH;4bYNqfHliYYPzZZk> M332OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GxMYRm\mmlaXXueEBpfW2jbjDNXFEh[2WubIOsJGVEPTBiPTCwMlAxPTNizszNMi=> NFq1[oY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Rosetta2 (DE3) NFj6[nJHfW6ldHnvckBie3OjeR?= NX;pTYRDUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIE\4bIl{NXSjZ3fl[EBCWlSGNjCoPFc{KHSxIEGxOlEqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIGLvd4V1fGF{IDjESVMqKGOnbHzzJJV{cW6pIF7BSEsh[XNic4Xid5Rz[XSnIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4> NHjlV|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc4OCd-MkS5NFA4PzB:L3G+
Rosetta2 (DE3) MojLSpVv[3Srb36gZZN{[Xl? MlznTY5pcWKrdHnvckBw\iCqdX3hckA3gGircz30ZYdo\WRiQWLUSFUhMDFyM{CgeI8hOTNzNzmg[ZhxemW|c3XkJIlvKEW|Y3jldolkcGmjIHPvcIkhWm:|ZYT0ZVIhMESHMzmgZ4VtdHNidYPpcochVkGGKzDhd{B{fWK|dILheIUh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxKD1iMD6wNlUh|ryPLh?= M3iycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
LoVo M1jpXmN6fG:2b4jpZ4l1gSCjc4PhfS=> MmXVNE41KHWP NUjW[JFxPSCmYYnz Mnj6VI91\W62aXH0bY9vKG:oIITlcY97d2yxbXnk[U1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCrbjDoeY1idiCOb2\vJINmdGy|IHHzd4V{e2WmIHHzJJRmdW:8b3zvcYll\SCJSUWwJIF1KDBwNDD1UUBi\nSncjC1JIRigXNiYomgR4VtdHSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOTR2IN88UU4> NI\Zbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Capan1 MXHDfZRwfG:6aXPpeJkh[XO|YYm= MkLpR5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUKt[IVncWOrZX70JIh2dWGwIFPhdIFvOSClZXzsd{whTUN3MDC9JFAvPjB7IN88UU4> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MDA-MB-436 NIH6UZpCdnSrY3HuZ4VzKGG|c3H5 MnzuPVYhcHK| M3W4OmFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCVmNCOS2mZX\pZ4lmdnRiTVTBMW1DNTR|NjDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOyEQvF2u NXnLcpdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N|QzQDZ6PD;hQi=>
OVCAR3 M{f2WWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4jLcVI1KGi{cx?= NF\CUJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTOyClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gN{4{OSEQvF2u NIfwWXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OlExPid-Mkm0OVYyODZ:L3G+
MRC5 MoXXR5l1d3SxeHnjbZR6KGG|c3H5 Mlv3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{whTUN3MDC9JFgvPTNizszNMi=> MnXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MCF7 NHW1RY5CdnSrY3HuZ4VzKGG|c3H5 NXXneXE6QTZiaILz NWnnbWVLSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFE6NjR5IN88UU4> M1OyS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{SyPFY5Lz5{NkO0Nlg3QDxxYU6=
A673 Mkj4dWhVWyCjc4PhfS=> M36zXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MkKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NH7INVlyUFSVIHHzd4F6 M13sUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq NWO3SmVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NGLibolyUFSVIHHzd4F6 Mn3QdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> M3zzUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NUDHeoRQeUiWUzDhd5NigQ>? M3;oSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? M1XhfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MYjxTHRUKGG|c3H5 NVr3W21TeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

24085845 27960087
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

23565244 27515310 30589644
体内研究 AG-014699无毒，明显增强D384Med移植瘤DNA修复功能蛋白中temozolomide诱导的TGD。药物动力学研究显示在脑组织中也检测到AG-014699，说明AG-014699用于治疗颅内恶性肿瘤具有潜在可能。[3]活体模型(NB1691和SHSY5Y移植瘤)研究显示AG-014699增强temozolomide的抗癌活性，产生彻底且持久的肿瘤衰退现象。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[3]
- 合并

激酶实验:

不同浓度(0到1μ)AG-014699作用于5×103D283Med 细胞，与只用DMSO处理5×103D283Med细胞相比，来测定PARP活性抑制率。参考GCLP验证试验的PAR标准曲线，在和NAD+及寡核苷酸(底物和激活剂)温育的6分钟期间，使用10H PAR抗体，通过PAR形成量的免疫检测，在细胞样本中测量最大程度刺激的PARP活性。
细胞实验： [3]
- 合并
  • Cell lines: D425Med, D283Med和D384Med细胞
  • Concentrations: 0.4 μM
  • Incubation Time: 3或5天
  • Method: 髓母细胞瘤细胞系包含D425Med, D283Med，和D384Med细胞，分别按1×103, 3×103，和3×103密度接种在96孔板上。接种24小时(D384Med细胞)或48小时(D283Med和D425Med细胞)后，细胞用不同浓度temozolomide处理。培养3天(D425Med和D384Med细胞)或5天(D283Med细胞)后，通过XTT细胞增殖检测试剂盒检测细胞活力。用DMSO处理的对照组和0.4μ AG-014699处理的实验组的百分比表示细胞生长。计算temozolomide单独使用或者和AG-014699联用时的GI50值。Temozolomide单独使用时的GI50值和与AG-014699联用时的GI50值之比就是趋化因子50（PF50）值。
    (Only for Reference)
动物实验：[3]
- 合并
  • Animal Models: 携带D283Med移植瘤的CD-1裸鼠
  • Dosages: 1 mg/kg
  • Administration: 腹腔注射，每天1次或4次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.36
化学式

C19H18FN3O.H3PO4
CAS号 459868-92-9
储存条件 粉状
溶于溶剂
别名 PF-01367338

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

  • G007-LK New

    G007-LK是一种有效的选择性tankyrase抑制剂，对TNKS1/2的IC50分别为46 nM 和 25 nM。

  • NU1025 New

    NU1025 (NSC 696807)是一种有效的 PARP 抑制剂，IC50 为 400 nM。

  • Blasticidin S HCl New

    Blasticidin S HCl是一种从Stretomyces girseochromogenes中分离得到的核苷antibiotic，也是DNA和蛋白质合成的抑制剂，用于筛选携带brs或BSD抗性基因的转染细胞。

  • Olaparib (AZD2281)

    Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂，IC50为5 nM/1 nM，其对PARP1/2的作用比对Tankyrase-1效果高300倍。在BRCA突变的细胞中，Olaparib可以显著地诱导线粒体自噬相关的细胞自噬。

    Features:Olaparib是第一批PARP抑制剂之一。

  • Veliparib (ABT-888)

    Veliparib (ABT-888, NSC 737664)是一种有效的PARP1和PARP2抑制剂，无细胞试验中Ki分别为5.2 nM和2.9 nM，对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。

    Features:ABT-888增强常见癌症疗法的效果，比如放射疗法和烷基化剂。

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673, LT-673)是一种新型的PARP抑制剂，无细胞试验中对PARP1的IC50为0.57 nM。它也是有效的PARP-2抑制剂，但不抑制PARG，对PTEN突变型高度敏感。Phase 3。

    Features:到目前为止报道的最有效的选择性PARP抑制剂。

  • Iniparib (BSI-201)

    Iniparib (BSI-201, NSC-746045, IND-71677)是一种PARP1抑制剂，在三阴性乳腺癌(TNBC)中具有作用效果。Phase 3。

  • AG-14361

    AG14361是一种有效的PARP1抑制剂，无细胞试验中Ki为<5 nM。它比benzamides至少有效1000倍。

    Features:AG14361是第一个高效的PARP-1抑制剂，具有选择性和体内活性，增强化疗和放射治疗人类癌症。

Tags: 购买Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate供应商 | 采购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate价格 | Rucaparib (AG-014699) phosphate生产 | 订购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID